title: BR-MA, OM-MA, GI-MA and CEA: clinical evaluation using the IMMULITE analyzer.
abstract: This study was designed to clinically evaluate four tumour markers on the automated chemiluminescent immunoanalyser, IMMULITE, and to compare the data obtained with those of established immunoassays. IMMULITE BR-MA and CEA were compared to the CIS ELSA CA 15-3 and either the CIS CEA-ENZELSA or TOSOH (AIA 1200) CEA in 206 serum samples from 32 breast cancer patients. A parallel reaction was mainly observed between BR-MA and CA 15-3 assays which accorded well with the clinical situation. BR-MA was more sensitive in both progressive disease and stable disease than CA 15-3. Data from the CEA assays gave a parallel response in individual patients, but the sensitivity was lower compared to BR-MA/CA 15-3. IMMULITE OM-MA was compared to CIS ELSA CA 125 in 208 sera from 32 longitudinally followed ovarian cancer patients. In the majority of patients, a parallel response was observed; lower values were found with the OM-MA assay, but no clinical discrepancies were noted. IMMULITE GI-MA and CIS ELSA CA 19-9 were evaluated in 17 colorectal cancer patients (47 serum samples). In most of the patients, the data pattern was parallel, and differences in the absolute values were only observed in a few instances. In conclusion, the IMMULITE assays corresponded well with established methods, and the data obtained support their use in the management of cancer patients.
authors.affiliation: Department of Nuclear Medicine, Groene Hart Ziekenhuis, Gouda, The Netherlands.
authors.forename: A
authors.initials: A
authors.lastname: van Dalen
mesh_terms: D000911:Antibodies, Monoclonal / Q000276:immunology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000097:blood*; D001943:Breast Neoplasms / Q000097:blood*; D018394:CA-125 Antigen / Q000097:blood*; D018395:CA-19-9 Antigen / Q000097:blood*; D016190:Carboplatin / Q000008:administration & dosage; D002272:Carcinoembryonic Antigen / Q000097:blood*; D015179:Colorectal Neoplasms / Q000097:blood / Q000601:surgery; D003520:Cyclophosphamide / Q000008:administration & dosage; D004797:Enzyme-Linked Immunosorbent Assay; D005069:Evaluation Studies as Topic; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D016014:Linear Models; D008163:Luminescent Measurements; D018396:Mucin-1 / Q000097:blood*; D009362:Neoplasm Metastasis; D010051:Ovarian Neoplasms / Q000097:blood / Q000188:drug therapy; D011933:Reagent Kits, Diagnostic; D012015:Reference Standards; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D014408:Biomarkers, Tumor; D018394:CA-125 Antigen; D018395:CA-19-9 Antigen; D002272:Carcinoembryonic Antigen; D018396:Mucin-1; D011933:Reagent Kits, Diagnostic; D003520:Cyclophosphamide; D016190:Carboplatin